Its profit for the three months to December reached Rs 4,567 crore ($646.5 million), compared with Rs 3,043 crore a year earlier
Margin reduction of Oseltamivir in the US market cited as the major cause for the decline in profits during the quarter
Hindalco delivered the quarterly performance across all its businesses despite challenging environment and rising inputs cost
The company, which is undergoing Corporate Insolvency Resolution Process, had reported a net loss of Rs 361.28 crore in the October-December quarter of the previous fiscal
Total income grew 16.8 per cent to Rs 2,046.75 crore during the quarter, as against Rs 1,864.13 crore during the corresponding quarter a year ago
There was a tax adjustment of Rs 31.41 crore in the third quarter
For the nine month period ending December 31, 2018 total income was Rs 2,103.34 crore against Rs 2,422.83 crore
PC Jewellers' overall margin has improved on quarter-on-quarter as well as y-o-y basis
Apollo Hospitals' total income rose to Rs 2,177.15 crore in the quarter from Rs 1,864.13 crore a year ago.
JPVL has aggregate power generation capacity of 2,220 MW comprising of Hydro (400 MW) and Thermal (1,820 MW).
Tata Steel's consolidated gross debt has declined by Rs 9,083 crore during the quarter
Operating margins during the quarter contracted to 13.2% from 14.7% a year ago, due to higher raw material costs that the company was unable to pass on to buyers
Future group's revenue was up 43.2% to Rs 332.6 crore; company to increase use of automation going forward
The company had posted a net profit of Rs 1,135.92-crore for the same quarter a year ago, according to a regulatory filing
Abbott India's revenue from operations of the company stood at Rs 947.65 crore for the third quarter
UCO Bank's NPAs ballooned to 27.39% of gross loans at end of December 31, 2018
SAIL's total expenses fell to 14,937.43 crore in October-December 2018
Revenues from operations increased 21.5 percent to 5,269.7 crore during the quarter under review as compared to Rs 4336.1 crore in the year ago period
'We have delivered robust revenue growth of 22%', said Aurobindo Pharma MD N Govindarajan
OYO is operational in eight countries right now